At a Glance
- Company: Agilent Technologies Inc. (NYSE: A)
- Location: Canada (BIOVECTRA); Colorado (Nucleic Acid Solutions)
- Deal value: Reorganisation (no monetary figure disclosed)
- Focus area: Oligonucleotides, microbial fermentation, HPAPIs, cell development
- Next steps: Global client expansion, integrated service rollout
What happened?
Agilent Technologies launched Agilent Advanced Therapeutics on 11 March 2026, integrating its BIOVECTRA operations in Canada with Nucleic Acid Solutions in Colorado into a single CDMO platform. This unification spans US and Canada facilities for scalable therapy manufacturing.
Why does it matter?
CDMO demand surges for complex modalities like oligonucleotides and HPAPIs; Agilent’s integrated model reduces client handoffs, accelerates timelines and leverages North American capacity amid global supply constraints. Supports next-gen therapies from discovery to commercial scale.
Who’s behind it?
Agilent (18,000 employees, $6.95B FY2025 revenue) leads via Life Sciences and Diagnostics Group. BIOVECTRA handles fermentation/chemistry; Nucleic Acid Solutions focuses on nucleic acids. CEO Padraig McDonnell oversees strategy.
How was it achieved?
Combined assets deliver custom solutions: oligonucleotides, microbial fermentation, complex chemistry, HPAPIs and cell line development. Platform emphasises premium, scalable services across sites.
What’s next?
Roll out unified services to pharmaceutical/biotech partners worldwide; deepen technical collaborations for therapy commercialisation. Additional platform details on Agilent website.
What are people saying?
Padraig McDonnell: “Strengthens our ability to support customers… bring life-changing therapies to patients.” Simon May: “Combined excellence… advancing next generation of therapies.”